126 related articles for article (PubMed ID: 28842253)
61. Histone methyltransferases regulate the transcriptional expression of ERα and the proliferation of tamoxifen-resistant breast cancer cells.
Kim SS; Lee MH; Lee MO
Breast Cancer Res Treat; 2020 Feb; 180(1):45-54. PubMed ID: 31897900
[TBL] [Abstract][Full Text] [Related]
62. AKT3 regulates ErbB2, ErbB3 and estrogen receptor α expression and contributes to endocrine therapy resistance of ErbB2(+) breast tumor cells from Balb-neuT mice.
Grabinski N; Möllmann K; Milde-Langosch K; Müller V; Schumacher U; Brandt B; Pantel K; Jücker M
Cell Signal; 2014 May; 26(5):1021-9. PubMed ID: 24463007
[TBL] [Abstract][Full Text] [Related]
63. Checkpoint suppressor 1 suppresses transcriptional activity of ERα and breast cancer cell proliferation via deacetylase SIRT1.
Xu Z; Yang Y; Li B; Li Y; Xia K; Yang Y; Li X; Wang M; Li S; Wu H
Cell Death Dis; 2018 May; 9(5):559. PubMed ID: 29752474
[TBL] [Abstract][Full Text] [Related]
64. Steroid induction of therapy-resistant cytokeratin-5-positive cells in estrogen receptor-positive breast cancer through a BCL6-dependent mechanism.
Goodman CR; Sato T; Peck AR; Girondo MA; Yang N; Liu C; Yanac AF; Kovatich AJ; Hooke JA; Shriver CD; Mitchell EP; Hyslop T; Rui H
Oncogene; 2016 Mar; 35(11):1373-85. PubMed ID: 26096934
[TBL] [Abstract][Full Text] [Related]
65. Transcriptional modulation of BCRP gene to reverse multidrug resistance by toremifene in breast adenocarcinoma cells.
Zhang Y; Wang H; Wei L; Li G; Yu J; Gao Y; Gao P; Zhang X; Wei F; Yin D; Zhou G
Breast Cancer Res Treat; 2010 Oct; 123(3):679-89. PubMed ID: 19967559
[TBL] [Abstract][Full Text] [Related]
66. Hypoxia-inducible factor 1 alpha represses the transcription of the estrogen receptor alpha gene in human breast cancer cells.
Ryu K; Park C; Lee Y
Biochem Biophys Res Commun; 2011 Apr; 407(4):831-6. PubMed ID: 21458421
[TBL] [Abstract][Full Text] [Related]
67. Anticancer effect of metformin on estrogen receptor-positive and tamoxifen-resistant breast cancer cell lines.
Kim J; Lee J; Jang SY; Kim C; Choi Y; Kim A
Oncol Rep; 2016 May; 35(5):2553-60. PubMed ID: 26986571
[TBL] [Abstract][Full Text] [Related]
68. Different epigenetic mechanisms of ERα implicated in the fate of fulvestrant-resistant breast cancer.
Tsuboi K; Kaneko Y; Nagatomo T; Fujii R; Hanamura T; Gohno T; Yamaguchi Y; Niwa T; Hayashi SI
J Steroid Biochem Mol Biol; 2017 Mar; 167():115-125. PubMed ID: 27888136
[TBL] [Abstract][Full Text] [Related]
69. MicroRNA-135b regulates ERα, AR and HIF1AN and affects breast and prostate cancer cell growth.
Aakula A; Leivonen SK; Hintsanen P; Aittokallio T; Ceder Y; Børresen-Dale AL; Perälä M; Östling P; Kallioniemi O
Mol Oncol; 2015 Aug; 9(7):1287-300. PubMed ID: 25907805
[TBL] [Abstract][Full Text] [Related]
70. Neo-tanshinlactone selectively inhibits the proliferation of estrogen receptor positive breast cancer cells through transcriptional down-regulation of estrogen receptor alpha.
Lin W; Huang J; Liao X; Yuan Z; Feng S; Xie Y; Ma W
Pharmacol Res; 2016 Sep; 111():849-858. PubMed ID: 27491559
[TBL] [Abstract][Full Text] [Related]
71. MiR-301a-3p Suppresses Estrogen Signaling by Directly Inhibiting ESR1 in ERα Positive Breast Cancer.
Lettlova S; Brynychova V; Blecha J; Vrana D; Vondrusova M; Soucek P; Truksa J
Cell Physiol Biochem; 2018; 46(6):2601-2615. PubMed ID: 29763890
[TBL] [Abstract][Full Text] [Related]
72. Estrogen-mediated post transcriptional down-regulation of breast cancer resistance protein/ABCG2.
Imai Y; Ishikawa E; Asada S; Sugimoto Y
Cancer Res; 2005 Jan; 65(2):596-604. PubMed ID: 15695404
[TBL] [Abstract][Full Text] [Related]
73. Opposing effects of Runx2 and estradiol on breast cancer cell proliferation: in vitro identification of reciprocally regulated gene signature related to clinical letrozole responsiveness.
Chimge NO; Baniwal SK; Luo J; Coetzee S; Khalid O; Berman BP; Tripathy D; Ellis MJ; Frenkel B
Clin Cancer Res; 2012 Feb; 18(3):901-11. PubMed ID: 22147940
[TBL] [Abstract][Full Text] [Related]
74. Mechanisms of estrogen receptor-α upregulation in breast cancers.
Miyoshi Y; Murase K; Saito M; Imamura M; Oh K
Med Mol Morphol; 2010 Dec; 43(4):193-6. PubMed ID: 21267694
[TBL] [Abstract][Full Text] [Related]
75. Changes in breast cancer transcriptional profiles after treatment with the aromatase inhibitor, letrozole.
Miller WR; Larionov AA; Renshaw L; Anderson TJ; White S; Murray J; Murray E; Hampton G; Walker JR; Ho S; Krause A; Evans DB; Dixon JM
Pharmacogenet Genomics; 2007 Oct; 17(10):813-26. PubMed ID: 17885619
[TBL] [Abstract][Full Text] [Related]
76. MYSM1 acts as a novel co-activator of ERα to confer antiestrogen resistance in breast cancer.
Luan R; He M; Li H; Bai Y; Wang A; Sun G; Zhou B; Wang M; Wang C; Wang S; Zeng K; Feng J; Lin L; Wei Y; Kato S; Zhang Q; Zhao Y
EMBO Mol Med; 2024 Jan; 16(1):10-39. PubMed ID: 38177530
[TBL] [Abstract][Full Text] [Related]
77. Estrogen Receptor on the move: Cistromic plasticity and its implications in breast cancer.
Mayayo-Peralta I; Prekovic S; Zwart W
Mol Aspects Med; 2021 Apr; 78():100939. PubMed ID: 33358533
[TBL] [Abstract][Full Text] [Related]
78. aP2-Cre-mediated inactivation of estrogen receptor alpha causes hydrometra.
Antonson P; Matic M; Portwood N; Kuiper RV; Bryzgalova G; Gao H; Windahl SH; Humire P; Ohlsson C; Berggren PO; Gustafsson JÅ; Dahlman-Wright K
PLoS One; 2014; 9(1):e85581. PubMed ID: 24416430
[TBL] [Abstract][Full Text] [Related]
79. Positive Regulation of Estrogen Receptor Alpha in Breast Tumorigenesis.
Porras L; Ismail H; Mader S
Cells; 2021 Oct; 10(11):. PubMed ID: 34831189
[TBL] [Abstract][Full Text] [Related]
80. Estrogen Receptor Alpha Mutations, Truncations, Heterodimers, and Therapies.
Hancock GR; Gertz J; Jeselsohn R; Fanning SW
Endocrinology; 2024 Apr; 165(6):. PubMed ID: 38643482
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
